




DNA methylation biomarkers in peripheral blood of patients with head and neck
squamous cell carcinomas. A systematic review
Danstrup, Christian Sander; Marcussen, Mette; Pedersen, Inge Søkilde; Jacobsen, Henrik;
Dybkær, Karen; Gaihede, Michael
Published in:
PLOS ONE







Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Danstrup, C. S., Marcussen, M., Pedersen, I. S., Jacobsen, H., Dybkær, K., & Gaihede, M. (2020). DNA
methylation biomarkers in peripheral blood of patients with head and neck squamous cell carcinomas. A
systematic review. PLOS ONE, 15(12), [e0244101]. https://doi.org/10.1371/journal.pone.0244101
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
RESEARCH ARTICLE
DNA methylation biomarkers in peripheral
blood of patients with head and neck
squamous cell carcinomas. A systematic
review
Christian Sander DanstrupID
1,2*, Mette Marcussen2, Inge Søkilde Pedersen2,3,4,
Henrik Jacobsen1, Karen Dybkær2,4,5, Michael Gaihede1,4
1 Department of Otorhinolaryngology–Head & Neck Surgery and Audiology, Aalborg University Hospital,
Aalborg, Denmark, 2 Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark,
3 Department of Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark, 4 Department of





Head and neck squamous cell carcinomas (HNSCC) are often diagnosed in advanced
stages. In search of new diagnostic tools, focus has shifted towards the biological properties
of the HNSCC, and the number of different biomarkers under investigation is rapidly
growing.
Objectives
The objective was to review the current literature regarding aberrantly methylated DNA
found in peripheral blood plasma or serum in patients with HNSCC and to evaluate the diag-
nostic accuracy of these changes.
Methods
The inclusion criteria were clinical studies involving patients with verified HNSCC that
reported findings of aberrantly methylated DNA in peripheral blood serum or plasma. We
systematically searched PubMed, OVID Embase and Cochrane Library. In addition to the
search, we performed forward and backward chaining in references and Web of Science.
The protocol was registered in PROSPERO: CRD42019135406. Two authors indepen-
dently extracted data. The quality and the risk of bias of the included studies were assessed
by the QUADAS-2 tool.
Results
A total of 1,743 studies were found eligible for screening, while ultimately seven studies
were included. All studies were found to have methodological weaknesses, mainly
PLOS ONE







Citation: Danstrup CS, Marcussen M, Pedersen IS,
Jacobsen H, Dybkær K, Gaihede M (2020) DNA
methylation biomarkers in peripheral blood of
patients with head and neck squamous cell
carcinomas. A systematic review. PLoS ONE
15(12): e0244101. https://doi.org/10.1371/journal.
pone.0244101
Editor: Mariana Brait, Johns Hopkins University,
UNITED STATES
Received: April 24, 2020
Accepted: December 2, 2020
Published: December 17, 2020
Copyright: © 2020 Danstrup et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This study has been supported by
Department of Clinical Medicine, Aalborg University
and Department of Otorhinolaryngology – Head &
Neck Surgery and Audiology, Aalborg University
Hospital, Denmark. The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
concerning patient selection bias. The best individual marker of HNSCC was Septin 9 in
plasma with a sensitivity of 57% and a specificity of 95%.
Conclusions
None of the aberrantly methylated genes found in the retrieved studies are applicable as sin-
gle diagnostic markers for HNSCC and the best gene-panels still lack diagnostic accuracy.
Future studies may benefit from newer sequencing techniques but validation studies with
well-designed cohorts are also needed in the process of developing epigenetic based diag-
nostic tests for HNSCC.
Introduction
Head and neck cancer represents 4% of all malignancies with more than 650.000 new cases
worldwide each year, where the majority of these cancers are squamous cell carcinomas
(HNSCC) [1–3]. The overall 5 year survival of the patients is 60%, and it has improved only
moderately over the last decades [4–6]. A major reason for this is probably that patients with
HNSCC often present at later stages of their disease (III-IV as defined by the American Joint
Committee on Cancer (AJCC) cancer staging manual [7]). Survival is inversely related to dis-
ease stage [8], and for patients with oro- and hypopharyngeal cancers, 72–75% present with
late stages, with a 5 year survival rate below 50% [9, 10]. Smoking and alcohol consumption
are major risk factors in HNSCC [11], however, the role of human papillomavirus (HPV) has
within the last 10 years been increasingly recognized as a factor, particularly in the develop-
ment of oropharyngeal cancer [12].The HPV-related oropharyngeal carcinomas have a better
prognosis and show better response to treatment [13]. The differences between HPV-related
and non HPV-related oropharyngeal carcinomas have caused that separate staging systems
were established in the eighth edition of AJCC cancer staging manual [7].
In search of tools for earlier diagnosis, improved prognostic evaluation and detection of
recurrent disease, focus has shifted towards the biological properties of HNSCC, and the num-
ber of biomarkers under investigation is rapidly growing. Initially, proteins and later changes
in DNA, RNA (microRNA), and circulating tumor cells have been investigated. A particular
evolving branch of DNA-research is epigenetic changes, where DNA-methylation represents
one of the most studied modifications. This consists of the addition of a methyl (CH3) residue
in a cytosine base proceeding a guanosine base, known as a CpG dinucleotide; in normal
human DNA 3–6% of all cytosines are methylated [14].
Most CpG dinucleotides are found in CpG-rich regions, known as CpG islands [15]. 55–
75% of human genes have been reported to have CpG rich promoters, and these are predomi-
nantly unmethylated in normal tissue [16, 17]. In the development of cancers, aberrant meth-
ylation of promoter-regions is of particular interest, as hypermethylation of tumor-suppressor
genes may result in downregulation of the activity of the tumor suppressor function, while
hypomethylation of promoter regions in oncogenes may result in an increased gene expression
[18–21].
Cell-free DNA (cfDNA) from solid tumors has been demonstrated in the bloodstream.
While the exact mechanism behind such release of cfDNA is still debated, apoptotic and
necrotic cells are thought to be the origin [22, 23]. If these DNA-fragments can be detected
and their methylation-status determined, this holds the potential of becoming an important
tool in early demonstration and diagnosis of malignant solid tumors. In several types of malig-
nant solid tumors, but not HNSCC, commercial tests based on aberrant methylation are
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already available (e.g. the Epi proColon1 and Cologuard1 for colorectal-cancer screening and
the Epi proLung1 in detection of lung cancer) [24–29].
Based on this background, the primary objective of this paper was to review the current lit-
erature of the usage of aberrantly methylated DNA found in the peripheral blood plasma or
serum of patients with HNSCC and evaluate the diagnostic accuracy of these changes. A sec-
ond objective was to evaluate the potential prognostic value of such findings.
Materials and methods
We conducted a systematic review according to the Preferred Reporting Items for Systematic
review and Meta-analysis (PRISMA) guidelines (S1 Checklist) [30]. The protocol was regis-
tered in the PROSPERO database for systematic reviews with registration number:
CRD42019135406 [31].
Inclusion criteria
Clinical studies involving patients with histopathologically verified HNSCC that reported find-
ings of aberrantly methylated DNA in peripheral blood serum or plasma were eligible.
Exclusion criteria
Studies were excluded, if they were: (1) performed in animals; (2) only describing aberrantly
methylated DNA in solid tumors; (3) published only as conference abstracts; (4) published
only in a review; or (5) published in a language other than English.
Search strategy
In June 2019, we performed a systematic literature search in OVID Embase, PubMed and
Cochrane Library. No limits were placed on the publication dates in our search. In addition to
the search, we performed forward and backward chaining in references and Web of Science.
The search strategy was structured by one reviewer (C.D.) in collaboration with Pernille
Gaardsted, research librarian at the Medical Library, Aalborg University Hospital. An updated
search was performed in March 2020. The full search strategy appears in S1 Table.
Study selection
Papers found according to our search strategy were imported into the Covidence online soft-
ware (Covidence, Melbourne AUS for data management and literature screening [32]). After
duplicate removal, one reviewer (C.D.) screened titles and abstracts of all potential studies
using the inclusion criteria. Then all full text articles were assessed for eligibility by two inde-
pendent reviewers (C.D., M.M.). Any disagreement was resolved by consensus. A flowchart
showing the study selection process in according to PRISMA was generated (Fig 1).
Data collection process
Two authors (C.D., M.M.) independently extracted data and assessed the risk of bias in the
included studies. Data extraction included the name of first author, year of publication, num-
ber of HNSCC cases, number of controls, medium examined (plasma/serum), type of methyla-
tion analysis used, diagnostic performance, prognostic value of the methylation status in
HNSCC patients measured by recurrence free survival and overall survival. Any disagreement
was resolved by consensus.
Due to the heterogenicity of the included studies a meta-analysis was not considered mean-
ingful and a structured narrative synthesis was performed.
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Quality assessment and assessment of the risk of bias
The quality and the risk of bias of the included studies were assessed by the QUADAS-2 tool
[33]. The tool is designed to assess the quality of primary diagnostic accuracy studies. The follow-
ing domains were evaluated: Patient selection, index test, reference standard, flow and timing.
Results
A total of 2428 studies were imported into Covidence. After removal of duplicates by Covi-
dence (685) a total of 1743 studies were eligible for screening according to the inclusion
Fig 1. PRISMA flow diagram. From Moher et al. [30].
https://doi.org/10.1371/journal.pone.0244101.g001
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criteria. The screening process resulted in the removal of 1705 papers (incl. two duplicates
found during the screening) and left 38 papers for assessment. The full text assessment resulted
in the further exclusion of 31 studies and the inclusion of a total of 7 studies for final analysis
[34–40] (Fig 1). The reference lists of the included articles were screened for additional rele-
vant articles, but none met the inclusion criteria.
The earliest study was performed in 2000 [40], and the latest studies performed in 2017 [37,
38]. Six of the seven studies used gene panels based on results derived from earlier published
studies of HNSCC or other malignant tumors (e.g. lung, breast and colorectal cancers), while
Mydlarz et al. chose a panel based on own earlier findings in saliva [35]. All studies evaluated
the methylation status of the primary tumor and of peripheral blood, serum, or plasma with
focus on a limited number of genes. None of the investigators performed a broad or genome-
wide analysis. The studies show a large variation in included number of cases and controls.
Thus, 425 HNSCC patients were included in the study by Schröck et al. [37], contrasting the
17 patients with oral cancer described by Nakahara et al. [39].
It is noteworthy that studies [37, 38] are from the same research group and that studies [34,
35, 40] are also from one group.
Results from studies of methylation in serum
In 2008, Carvalho et al. [34] published a study on evaluation of promoter hypermethylation in
body fluids as a diagnostic tool in patients with HNSCC and healthy controls using quantita-
tive methylation-specific polymerase chain reaction (qMSP). They examined a panel of 21
genes that previously were described as hypermethylated in HNSCC or other solid tumors. Six
genes found in serum were significantly associated with HNSCC. Hypermethylation of each
gene was treated as a binary variable (methylation versus no methylation) and each gene was
evaluated separately and combined in a panel of the best possible combinations regarding sen-
sitivity and specificity (Table 1).
The performances of the selected panels were explored using multivariable logistic regres-
sion and receiver operating characteristic (ROC) curves. Internal validation of the logistic
regression was done by using an approximation to the leave-one-out jackknife procedure. Of
the six genes only one, Hypermethylated in Cancer 1 (HIC1), was considered useful as a diag-
nostic single-gene-marker with a sensitivity of 31.4% and a specificity of 92.5%. No combina-
tions of the selected genes were able to surpass the specificity of HIC1. A panel of five genes
showed a sensitivity of 87.2% and a specificity of 42.3%.
In their study, Mydlarz et al. [35] evaluated 100 HNSCC patients and 50 controls using
qMSP to detect hypermethylated Endothelin Receptor Type B (EDNRB), Deleted in Colorectal
Cancer (DCC) and Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A). Detection of hyper-
methylation was interpreted in a binary fashion without any cut-off as no methylation was
found in normal serum. In the HNSCC group, genes were hypermethylated in 10%, 2% and
1%, respectively. No hypermethylation of the specific genes could be demonstrated in the con-
trol group. There was no significant association between serum positivity for hypermethylated
genes and local recurrence free and overall survival (Table 2).
In another study, Nakahara et al. [39] examined hypermethylation of CDKN2A in biopsies
and serum of 17 oral squamous cell carcinoma (OSCC) patients and eight healthy controls
using MSP. Methylation was treated as a binary outcome. They found a sensitivity of 35% and
a specificity of 100% in serum. The authors performed pre- and post-treatment serum analy-
ses, and all patients with aberrant methylation in serum before treatment were non-methylated
at two months post-treatment follow up. Four patients had recurrence and three of these
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Stage Specimen Sensitivity Specificity AUC Method Reference
CDH1 Cadherin 1 62/320 All NA Serum 32% 73% 0.53 qMSPb Carvalho
et al. [34]
(2008)




Factor Beta Receptor 2















52/203 All NA Serum 8% 98% 0.53 qMSPb Carvalho
et al. [34]
(2008)
SEPT91 Septin 9 137/170 - All All Plasma 62% 92% 0.79 quasi-
digital
PCR
De Vos et al.
[38] (2017)
SHOX21 Short Stature Homeobox 2 137/170 - All All Plasma 53% 87% 0.78 quasi-
digital
PCR
De Vos et al.
[38] (2017)
SEPT92 Septin 9 141/102 - All All Plasma 55% 90% 0.75 quasi-
digital
PCR
De Vos et al.
[38] (2017)
SHOX22 Short Stature Homeobox 2 141/102 - All All Plasma 43% 95% 0.77 quasi-
digital
PCR
De Vos et al.
[38] (2017)
EDNRB Endothelin Receptor Type
B
100/50 - All All Serum 10% 100% qMSPb Mydlarz
et al. [35]
(2016)
DCC Deleted in Colo-rectal
Cancer
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patients, had aberrant methylation in the peripheral blood. In addition, all three had aberrant
methylation in both tumor and serum prior to treatment.
Using MSP for either methylated or unmethylated sequences, Sanchez-Cespedes et al.
[40] published a study in 2000 examining aberrant methylation of four genes, CDKN2A,
06-methylguanine-DNA-methyltransferase (MGMT), Death-associated protein kinase
(DAPK), Glutathione S-transferase P1 (GSTP1). Out of 95 HNSCC tumor and serum
samples, 52 patients had aberrant methylation in the primary tumor. MSP was unsuccess-
ful in two cases and therefore only 50 serum samples were evaluated. Twenty-one of 50
patients had the same methylation changes in the serum as in the primary tumor.
CDKN2A was positive in eight serum samples, MGMT in 14 and DAPK in three. GSTP1
hypermethylation was not found in any tumor or serum sample. As control subjects, they
analyzed serum of 25 patients, who did not have aberrant methylation in the primary
tumor. None of the serum samples in the control group, showed aberrant methylation of
the four genes. Seven of the patients had a new serum sample post-treatment. None of the
methylation-negative patients had converted, however, one DAPK-positive patient had











Stage Specimen Sensitivity Specificity AUC Method Reference
GSTP1 Glutathione S-transferase
p1




SHOX21 Short Stature Homeobox 2 137/122 - All All Plasma 50% 95% 0.80 qPCR Schröck
et al. [37]
(2017)
SEPT91 Septin 9 137/122 - All All Plasma 57% 95% 0.79 qPCR Schröck
et al. [37]
(2017)
SHOX22 Short Stature Homeobox 2 141/102 - All All Plasma 0.79 qPCR Schröck
et al. [37]
(2017)

























a: Methylation specific PCR.
b: Quantitative methylation specific PCR.
c: Combined bisulfite restriction analysis.
1: Training Cohort.
2: Testing cohort.
�The test is between OSCC and OP. No healthy controls.
https://doi.org/10.1371/journal.pone.0244101.t001
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Results from studies of methylation in plasma
Short Stature Homeobox 2 (SHOX2) and Septin 9 (SEPT9) have been examined by Schröck
et al. and De Vos et al. [37, 38]. First, a training cohort with 284 patients with HNSCC and 122
matched healthy controls and a test cohort with 141 patients with HNSCC and 102 matched
healthy individuals were tested for these two biomarkers with triplex quantitative PCR. Only
137 of 284 patients with HNSCC in the training cohort, had baseline blood plasma samples
available. The authors introduced a methylation cut-off value to dichotomize the methylation
values and levels below these values were considered sporadic background methylation.
Matched tumor samples and pretherapeutic methylation in plasma from 55 patients were ana-
lyzed [37]. SHOX2 methylation in plasma correlated significantly with tissue levels (Spear-
man’s p = 0.36, P = 0,007), while SEPT9 showed a suggestive trend (Spearman’s p = 0.25,
P = 0.067). ROC curves have been computed as a measure of diagnostic accuracy and in the
training cohort SHOX2/SEPT9 sensitivity and specificity were reported to be 59% and 96%,
respectively (Table 1). Using univariate Cox proportional hazard analysis for both cohorts, the
authors found a significantly higher risk of death for methylation positive patients for both
markers [37, 38] (Table 2).
In their second study [38], the team evaluated three different algorithms to asses methylated
cfDNA; Relative quantification, Absolute quantification and Quasi-Digital PCR. They used the
same two markers (SEPT9 and SHOX2) and almost the same training and testing cohort as in
their previous study [37], only adding 48 extra controls to the training cohort. All three
Table 2. Prognostic value of DNA methylation in plasma or serum.
Gene(s) Name Anatomical
site







All All 1.35c (0.17–10.5) 1.35c (0.41–4.43) qMSP Mydlarz et al.
[35]




All All - 2.32a (1.12–4.83) qPCR Schröck et al.
[37]
SEPT91 Septin 9 All All 1.32b (1.09–1.59) 1.23b (1.07–1.41) qPCR Schröck et al.
[37]




All All - 2.50a (1.12–5.60) qPCR Schröck et al.
[37]
SEPT91 Septin 9 All All - 1.90d (1.43–2.69) quasi-digital
PCR




All All - 1.85d (1.18–2.91) quasi-digital
PCR
De Vos et al.
[38]
SEPT92 Septin 9 All All - 1.67d (1.13–2.45) quasi-digital
PCR




All All - 1.71d (1.05–2.80) quasi-digital
PCR
De Vos et al.
[38]
a: Univariate cox proportional hazards analysis of the 129 cases with positive serum samples using the introduced cut-off value.
b: Multivariate cox proportional hazards analysis of the 129 cases using the DNA methylations levels as a continuous variable.
c: Univariate proportional hazards analysis.
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algorithms showed similar Area Under the Curve (AUC) in the ROC curves (Performance for
Quasi-Digital PCR can be found in Table 1). In prognostic evaluation in both cohorts, all three
algorithms also showed significantly increased hazard ratios for methylation positive patients
(Performance for Quasi-Digital PCR can be found in Table 2).
Finally, Wong and colleagues [36], used real time PCR to examine promoter methylation of
the p16 and p15 genes in plasma. Methylated p16 was found in 65% of the patients with HNSCC
in contrast to 20% of the healthy controls. Methylated p15 was seen in the plasma of 60% of the
patients with HNSCC and in 50% of the healthy controls. The mean concentration of methylated
p16 and p15 was significantly higher in HNSCC patients compared to healthy controls (p = 0.016
and 0.0037 respectively), but no cut-off values for background methylation was defined.
Risk of bias
The QUADAS-2 evaluation of the included studies showed that all studies had a high or
unclear risk of bias related to patient selection. None of the studies explicitly described how
patients or controls were enrolled, e.g. consecutively or randomly or other criteria. Further-
more, all the studies were case control by design. All index-tests were interpreted with the
knowledge of the reference standard in the HNSCC groups. None of the included studies
described the precise flow and timing regarding time from diagnosis to biopsy and blood sam-
pling. (An overview of the QUADAS-2 evaluation appears in Table 3).
Applicability concerns
There were no concerns regarding the condition as defined by the reference standard in any of
the included studies. One study [40], was graded as unclear concerning the index test, as no
healthy control group was included.
Two studies [27, 30], did not report any information on the control groups, and they were
judged as unclear regarding patient selection. As no healthy control group was defined in the
study by Sanchez-Cespedes et al. [40], the concern regarding patient selection was high. The
remaining four studies [34, 35, 37, 38], were judged as low as they had matched control groups
and provided tables with demographic information regarding age, gender, tobacco- and alco-
hol consumption. (An overview of the applicability concerns is given in Table 3)
Discussion
Epigenetic changes, including aberrant DNA methylation, in human cancers was initially
described more than thirty years ago [41]. With the development of new laboratory techniques
Table 3. Risk of bias and applicability concerns.















Carvalho et al. [34] High High Low Unclear Low Low Low
Mydlarz et al. [35] Unclear High Low Unclear Low Low Low
Nakahara et al. [39] High High Low Unclear Unclear Low Low
Sanchez-Cespedes
et al. [40]
Unclear High Low Unclear High Unclear Low
Schröck et al. [37] High High Low Unclear Low Low Low
De Vos et al. [38] High High Low Unclear Low Low Low
Wong et al. [36] High High Low Unclear Unclear Low Low
https://doi.org/10.1371/journal.pone.0244101.t003
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and assays, the ability to examine body fluids, especially blood, for circulating tumor cells or
tumor DNA has inspired the search of new diagnostic and prognostic tools in cancer. The
objective of this review was to provide an overview of aberrantly methylated DNA found in
plasma or serum of peripheral blood and their diagnostic and prognostic potential in patients
with HNSCC.
The majority of the studies, we retrieved in this systematic review, described both sensitivity
and specificity of the different aberrantly methylated genes, whereas the study by Sanchez-
Cespedes et al. [40] did not include a healthy control group, so that specificity could not be
calculated.
Not all included studies presented both diagnostic and prognostic data, as only three studies
[35, 37, 38], described follow-up, and therefore, they were able to calculate hazard ratios on
local recurrence free survival and overall survival.
Both single genes and gene-panels were evaluated. The best individual marker was found
by Schröck et al. [37] as detected hypermethylated SEPT9 in plasma had a 57% sensitivity and
95% specificity. Hypermethylated SEPT9 was also assessed in studies of other solid tumors,
e.g. the Epi proColon1 that is a commercially available blood-based DNA hypermethylation
test screening for colorectal cancer. As a single marker, the assay reached a sensitivity of 48.2%
and specificity of 91.5% in a large prospective study with 6874 asymptomatic patients sched-
uled for colorectal cancer screening [42].
When combining both SHOX2 and SEPT9 (MeanShox2/SEPT9), Schröck et al. [37] demon-
strated that the sensitivity and specificity can be improved to 59% and 96%, respectively. In the
study by Carvalho et al. [34] the best combined gene panel generated a sensitivity of 87% and a
specificity of 42%. Their study was limited by the fact that not all genes were analyzed in all
HNSCC- and control samples.
Anatomical subsite, stage and HPV status
The anatomical subsite and HNSCC tumor stage may also play a role in the release of tumor
DNA, and hence, the methylation-findings in peripheral blood. Thus, tumors in subsites with
rich lymphatic drainage and blood supply may possibly be detected earlier. For example, the
lymphatic drainage and blood supply of the larynx is remarkably different to other subsites
due to the dual embryological origin [43]. Tumor size may also play a role, as small T1 tumors
of the larynx will present a small cell-turnover compared to a large invasive T4b supraglottic
tumor invading the prevertebral space.
The incidence of HPV-related HNSCC has been increasing during the last decades and is
now described as an independent subtype with a distinct morphological profile and occurs pri-
marily in the oropharynx of younger patients without tobacco and alcohol as co-factors [44,
45]. It has been shown that expression of the p16 protein is highly correlated to HPV in oro-
pharyngeal cancer where the protein is upregulated in contrast to non HPV-related HNSCC.
Due to this strong correlation, immunohistochemical analysis of p16 are used as a surrogate
marker of HPV-related HNSCC [46].
This etiological linkage and role of HPV should be taken into consideration when evaluat-
ing methylation profiles as these may differ between HPV-related and non HPV-related
HNSCC. This has been addressed by Delgi Esposti et al. [47]. Using pooled genome-wide anal-
yses they found that HPV infection affects the DNA methylation in HNSCC across different
anatomical subsites.
Of the seven studies included, only Mydlarz et al. [35] reported the HPV-status in their
HNSCC patients, but did not mention the method used to determine HPV-status. They
described the HPV- status related to survival but not in relation to the biomarkers examined.
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Five studies [34–36, 39, 40] evaluated methylation of the p16 promoter, but none described or
discussed the findings in relation to HPV and potential differences between HPV-related and
non HPV-related HNSCC.
The mechanism of DNA release into the circulation it not fully clarified. However, it is sug-
gested that circulating DNA is derived from apoptotic or neoplastic cells or from tumor cells
that are not capable of generating metastases [22, 23, 48]. Carvalho et al. [34] did not report
the tumor size and stage of the cancer patients examined, while Wong et al. [36] only reported
methylation status of the primary tumor in relation to tumor size. All positive samples in the
study by Mydlarz et al. [35] were Stage IV cancers and Schröck et al. [37] found a strong corre-
lation between the level of the biomarkers in plasma and tumor- and nodal-category.
This should be taken into consideration when evaluating blood-based biomarkers as
screening tools for HNSCC and if possible, anatomical subsite, HPV status, tumor size and
stage should be reported when evaluating the potential diagnostic and prognostic biomarkers.
Examination of plasma versus serum–flow and timing
The use of plasma and serum was almost equally distributed as four studies [34, 35, 39, 40],
evaluated methylation in serum, and three studies [36–38] evaluated methylation in plasma.
In general, the amount of cell free DNA is higher in serum compared to plasma (2–24
times). Therefore, serum is suggested as the best source for evaluation, however, Jung et al.
[49] examined the changes in the concentration of DNA in serum and plasma during storage
and handling of blood samples. They found no change in DNA concentration in plasma stored
8h at room temperature, but time delay and storage temperature had significant impact (3.8–
4.8 times higher for samples stored 2-8h at room temperature) on the concentration of DNA
in serum.
Of the included studies, only Schröck et al. [37] and De Vos et al. [38] explicitly described
the plasma preparation regarding timing, as plasma were prepared within 2h after sampling.
None of the included studies described the flow and timing between the biopsy (histologi-
cally verifying the diagnosis) and the blood samples. If a large biopsy in a vascularized field is
taken, it may cause a release of tumor-cells in the bloodstream, and hence, an elevation of
cfDNA in the blood sample afterwards. Henriksen at al. demonstrated that total cfDNA levels
were elevated up to four weeks after surgery in patients undergoing colorectal cancer surgery
[50]. Therefore, when studying biomarkers potentially released from tumor tissue, the study
should preferable include a measurement the DNA methylation status before (and after) the
primary biopsy with documented flow and timing, or at least describe the flow of sample
collection.
Cut-off values and background methylation
Only two studies [35, 39] did not find any aberrant methylation of the evaluated biomarkers in
the healthy control groups. The fact that the other studies find aberrant methylation in healthy
controls suggest that other factors may contribute to the methylation-level in general. This
issue was only addressed by Schröck and others [37] and defined as sporadic background
methylation. Therefore, a methylation level cutoff was introduced.
Wong et al. [36] evaluated the resection-margins of 29 smoking patients with HNSCC.
They found that methylation-levels of the p15 promoter were significantly higher in resection
margins (and histopathologic healthy tissue) in chronic smokers compared to non-smokers.
These findings have also been documented by others [51, 52]. When evaluating a biomarker as
a screening or diagnostic tool, it should be evaluated in a group of people at risk. Matched con-
trols regarding age, gender, use of tobacco, alcohol and general health-status should be
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preferred. Of the included studies, two failed to report demographics of their control patients,
hence introducing potential bias in the patient selection [36, 39].
Reflections of tumor-methylation in peripheral blood–concordance rate
All the included studies describe that methylation analyses of the primary tumors have been
performed, but not all described the concordance between tumor- and the serum-methylation.
Using Spearman correlation, Schröck et al. analyzed 55 matched tumor and blood samples
and found a significant correlation for SHOX2 but not for SEPT9. Sanchez-Cespedes et al.
[40] found that 42% of the examined patients had the same methylation changes in serum and
the primary tumor.
In the study of aberrantly methylated CDKN2A by Nakahara et al. [39], 54,5% of the
patients had matching tumor and serum changes. In a study of CDKN2A in 94 colorectal can-
cer patients, a concordance rate of 30% was found [53], and in a study of primary lung cancer
(using MSP) by Ooki et al., the concordance rate was between 20–56% in a six-gene panel [54].
None of the included studies had a perfect concordance rate of methylation in tumor and
plasma/ serum, which raises the question, why that is so. HNSCC are highly heterogeneous
tumors and different methylation-profiles may exist even within the tumor. Thus, different
biopsy-sites may yield different methylation-profiles. If different methylation-profiles exists,
this may also be reflected in the DNA released to the circulation.
Prognostic value of aberrant blood methylation in HNSCC and post-
treatment surveillance
Several studies have evaluated the prognostic value of aberrant methylation profiles in the pri-
mary tumors of HNSCC [55–59]. Of the included studies, only three [35, 37, 38] had follow-
up, thus describing local recurrence free- and overall survival. Mydlarz et al. [35] did not find a
significant association between local recurrence or overall survival and promoter hypermethy-
lation of the three genes examined (Table 2).
Schröck et al. [37] performed univariate proportional hazards analyses on both cohorts and
multivariate analyses on their training cohort. In the univariate analyses, patients with positive
plasma levels of either SEPT9 or SHOX2 were at higher risk of death compared to the methyla-
tion negative patients. In multivariate analyses of the 129 patients in their training cohort,
SEPT9 proved to be an independent prognostic factor regarding local recurrence free survival
(HR: 1.32 CI:1.09–1.59) and overall survival (HR:1.23 CI: 1.07–1.41) (Table 2). De Vos et al.
[38] found both SEPT9 and SHOX2 to be significant prognostic factors regarding overall sur-
vival in all tested quantification algorithms (Table 2).
Post-treatment evaluation of aberrant methylated DNA was only reported in two of the
seven studies included [39, 40]. Nakahara et al. found that all six patients with positive tests
with regard to pre-treatment aberrant methylated DNA had converted to negative tests two
months after treatment; four of these patients were later diagnosed with recurrent disease, and
three had converted back to positive tests [39]. Sanchez-Cespedes et al. reported from post-
treatment samples that in three patients with positive pre-treatment tests, only one patient
became negative after treatment, while in two patients’ tests were still positive at five to six
months of follow-up. It was not reported, whether these patients later had recurrent disease
[40]. The role of post-treatment profiles of aberrant methylated DNA in HNSCC remains
unclear. Symonds et al. reported conversion of positive to negative tests in 35 of 47 patients
with colorectal-cancer [60]. Thus, it seems relevant to pursue this aspect in patients with
HNSCC as it may reveal an important method for surveillance.
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Methods used in methylation analyses
The included studies use different methods in their methylation analyses. Methylation-specific
PCR (MSP) was one of the earliest methods used in methylation studies and was initially
described by Herman et al. in 1996 [61]. The method uses primers to recognize methylated-
and unmethylated CpG’s. The method is cost-effective, but has a disadvantage of false positives
results [62]. MSP have been used in two studies in this review, which are also two of the oldest
studies (Sanchez-Cespedes et al. in 2000 and Nakahara et al. in 2005).
Of more recent methods, Yokoi et al. named the quantitative methylation specific PCR
(qMSP) as the “gold standard” of methylation analyses in a review from 2017 [63]. qMSP has
been used in another two of the included studies [34, 35]. The group with Schröck and De Vos
used triplex quantitative PCR (qPCR) and Wong et al. used real time PCR [36].
There are several challenges in the detection and quantification of cfDNA. The amount of
circulating cfDNA from tumor is generally very limited and have a short half-life. Therefore,
the methods used are particularly susceptible to timing and workflow, and optimal standard-
ized methods are needed in order to obtain a high performance.
All the included studies used targeted assays covering only a few numbers of known pro-
moters. Recent technological progress has enabled whole genome methylation analyses e.g.
Methylated DNA immunoprecipitation sequencing (MeDIPseq), whole-genome bisulfite
sequencing or the Infinium MethylationEpic Array [64, 65]. Each method has its advantages
but common for all are the genome wide coverage compared to targeted assays.
Using comprehensive integrative molecular analyses of 10.000 specimens of primary
tumors across 33 types of cancer in The Cancer Genome Atlas, Hoadley et al. [66] shoved that
the influence of cell type was evident in DNA-methylation based clustering. Using MeDIP-seq,
Shen et al. [67] demonstrated detection of early-stage pancreatic cancer trough cfDNA in
plasma but also the potential of multi-cancer classification using the same protocol in a cohort
of 189 plasma samples from 7 different tumor types. Early-stage detection across >50 different
cancers, including HNSCC by analyzing methylation signatures in cfDNA with advanced
computational biology has also recently been described by Liu et al. [68].
Ideally, each subtype of cancer presents a unique, detectable cfDNA signature and a
genome-wide analysis with improved bioinformatics would be able to detect the cancer pres-
ent at an early stage and the cell or tissue of origin.
Methods used in bisulfite conversion
Despite using different PCR-methods, all the included studies use bisulfite treatment of puri-
fied DNA. Efficient bisulfite conversion of DNA prior to PCR or any other methylation analy-
sis is an important step. Incomplete conversion may result in overestimation of methylation.
Furthermore, bisulfite treatment may result in degradation and loss of DNA, especially when
using samples of less than 200 ng DNA. In these cases, more than 95% of the bisulfite-treated
DNA is lost, if using standard procedures [69]. However high recovery can be achieved
through a rapid bisulfite-treatment protocol [70]. The challenge regarding efficient bisulfite
conversion has also been addressed by Ørntoft and colleagues [71]. They compared 12 differ-
ent kits for bisulfite conversion of circulating cfDNA and found that mean recovery ranged
between 9 and 32% and a bisulfite conversion efficiency of 97–99.9%. Based on their findings,
they recommend that an integrated bisulfite conversion efficiency control should be integrated
in the protocol of studies examining methylation markers in cfDNA.
None of the included studies in this review had a description of DNA recovery and bisulfite
conversion efficiency in their methods, nor mentioned the bisulfite treatment as a crucial step
in their discussion.
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Conclusion
None of the examined genes found in this literature review are applicable as single diagnostic
markers for HNSCC, and the best gene-panels still lack diagnostic accuracy. All the included
studies evaluated predefined candidate genes based on earlier studies, and thus, future studies
evaluating diagnostic methylation-markers in HNSCC may benefit from the use of whole
genome sequencing, new microarray technology, and improved bioinformatics algorithms.
Methylation levels seem to correlate with tumor size, stage, and nodal involvement so the diag-
nostic challenge of HNSCC may remain in small tumors with none- or uncharacteristic symp-
toms, but new panels with refined computational biology may be able to overcome this
challenge.
Future evaluation of cfDNA methylation in peripheral blood could have a diagnostic as well
as prognostic value and could be used for post-treatment surveillance. This would potentially
improve the survival rate and reduce the treatment related morbidity in these patients by
enabling early detection and less invasive procedures in the post-treatment follow-up care.
In conclusion, further studies are needed that ideally include thorough documentation of
laboratory methods used and genome-wide analyses of single anatomical sites. This also
includes analysis of correlation between methylation in tumor and peripheral blood, the HPV
status, matched cases and controls, and sample size calculations. Altogether, these aspects may
contribute to an improvement of HNSCC treatment regarding survival and the overall quality
of life for these patients.
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